ODU Digital Commonsmetadata only
Real-World Anti-Amyloid Therapy Beyond Traditional Symptomatic Populations: A Longitudinal Case Series
alzheimer’s disease, anti-amyloid therapy, biomarkers, donanemab, lecanemab, longitudinal trajectories, preclinical stage, real-world evidence
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1001626
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.